Memorial Sloan Kettering Cancer Center
New York, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Mesothelioma
What is new in Mesothelioma research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- Atezolizumab 1200 mg in 20 ML InjectionPhase 3 · NCT04996017
- CarboplatinPhase 3 · NCT06097728 · NCT05579366 · NCT05001880 · NCT06535607 · NCT06057935
- CisplatinPhase 3 · NCT03760575 · NCT03228537 · NCT06097728 · NCT07234058 · NCT02535312 · NCT06535607 · NCT04328844 · NCT04847063 · NCT06057935 · NCT01064648 · NCT04491942
- GemcitabinePhase 3 · NCT07532902 · NCT07824986
- IpilimumabPhase 3 · NCT07532902 · NCT04300244 · NCT06097728 · NCT06362369 · NCT05647265 · NCT03907852
- NivolumabPhase 3 · NCT07532902 · NCT04300244 · NCT06097728 · NCT06362369 · NCT05647265 · NCT04162015 · NCT03907852 · NCT06638931
- PemetrexedPhase 3 · NCT03760575 · NCT06318286 · NCT06097728 · NCT04162015 · NCT04328844 · NCT06057935
- VinorelbinePhase 3 · NCT07824986
- VolrustomigPhase 3 · NCT06097728 · NCT06535607
- VT3989Phase 3 · NCT07824986 · NCT04665206
- [18F]FAPI-74Phase 2 · NCT06503146
- [18F]FDGPhase 2 · NCT06503146
- [68Ga]Ga-FAPI-46 PET/CTPhase 2 · NCT06790082
- 5-FUPhase 2 · NCT07532902 · NCT06535607
- AtezolizumabPhase 2 · NCT03228537 · NCT05765084 · NCT06444815 · NCT05001880 · NCT03074513
- BevacizumabPhase 2 · NCT05579366 · NCT05001880 · NCT03074513 · NCT07893340
- Biospecimen CollectionPhase 2 · NCT05001880
- BMS-986504Phase 2 · NCT07532902 · NCT07602946
- Brentuximab VedotinPhase 2 · NCT03007030
- Cadonilimab Combined with chemotherapyPhase 2 · NCT06416930
- Carboplatin (AUC 5)Phase 2 · NCT07234058
- Carboplatin/Cisplatin - Pemetrexed - PembrolizumabPhase 2 · NCT06155279
- CemiplimabPhase 2 · NCT07234058
- ChemotherapyPhase 2 · NCT02153229
- Cisplatin/CarboplatinPhase 2 · NCT06318286
- Computed TomographyPhase 2 · NCT05647265 · NCT05001880
- Cytoreductive SurgeryPhase 2 · NCT05001880
- Decitabine/cedazuridinePhase 2 · NCT05960773
- DOMVANALIMAB + ZIMBERELIMABPhase 2 · NCT06790706
- DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4Phase 2 · NCT06790706
- FianlimabPhase 2 · NCT07234058
- Fludarabine + Cyclophosphamide combinationPhase 2 · NCT03935893
- Hyperthermic Intraperitoneal ChemotherapyPhase 2 · NCT05001880
- Intensity Modulated Radiation TherapyPhase 2 · NCT00715611
- intrapleural photodynamic therapy with videothoracoscopyPhase 2 · NCT04400539
- Iparomlimab and Tuvoraleimab injection+Bevacizumab+Pemetrexed+CisplatinPhase 2 · NCT07514793
- Ipilimumab InjectionPhase 2 · NCT03918252
- Ipilimumab N01Phase 2 · NCT07893340
- IvonescimabPhase 2 · NCT06840834
- Ivonescimab Combined With ChemotherapyPhase 2 · NCT07885306 · NCT06875076 · NCT07885319
- LenvatinibPhase 2 · NCT04287829 · NCT06318286
- Magnesium sulfatePhase 2 · NCT05730816
- Magnetic Resonance ImagingPhase 2 · NCT05647265
- Nivolumab InjectionPhase 2 · NCT03918252 · NCT04400539
- Normal SalinePhase 2 · NCT05730816
- OlaparibPhase 2 · NCT04515836
- OT-101Phase 2 · NCT05425576
- PaclitaxelPhase 2 · NCT05107674 · NCT06535607
- pembrolizumabPhase 2 · NCT05544929 · NCT02414269 · NCT03760575 · NCT04287829 · NCT03126630 · NCT06318286 · NCT04897022 · NCT05579366 · NCT05732831 · NCT03546426 · NCT02628067
- Pemetrexed (Alimta)Phase 2 · NCT07234058
- pemetrexed and cisplatin or carboplatinPhase 2 · NCT00715611
- Pemetrexed DisodiumPhase 2 · NCT03228537 · NCT02535312 · NCT05001880 · NCT01064648
- Photodynamic TherapyPhase 2 · NCT02153229
- Photofrin 2.0 mg/kgPhase 2 · NCT02153229
- Pleurectomy/DecorticationPhase 2 · NCT00715611
- Positron Emission TomographyPhase 2 · NCT05647265 · NCT05001880
- Radical PleurectomyPhase 2 · NCT02153229
- Sacituzumab govitecan-hziyPhase 2 · NCT06477419
- SintilimabPhase 2 · NCT07893340
- Sintilimab, Bevacizumab , Pemetrexed , CisplatinPhase 2 · NCT06543069
- Sintilimab+Anlotinib+Pemetrexed+CisplatinPhase 2 · NCT05188859
- SpartalizumabPhase 2 · NCT04802876
- Surgical ProcedurePhase 2 · NCT05647265
- TislelizumabPhase 2 · NCT04802876 · NCT05238883
- TremelimumabPhase 2 · NCT01843374
- Tumor Infiltrating Lymphocytes (TIL)Phase 2 · NCT03935893
- UV1 vaccine + leukinePhase 2 · NCT04300244
- [18F]FAPI-74 PET/CTPhase 1/2 · NCT07705074
- [203Pb]Pb-PSV359Phase 1/2 · NCT06710756
- [212Pb]Pb-PSV359Phase 1/2 · NCT06710756
- A2B543Phase 1/2 · NCT06051695
- A2B694Phase 1/2 · NCT06051695
- AlintegimodPhase 1/2 · NCT06362369
- Anetumab RavtansinePhase 1/2 · NCT03126630
- BNCTPhase 1/2 · NCT06603987
- Cediranib MaleatePhase 1/2 · NCT01064648
- cyclophosphamidePhase 1/2 · NCT02414269 · NCT06885697 · NCT04577326 · NCT03907852 · NCT07510815
- Dendritic cell vaccinationPhase 1/2 · NCT05765084
- Durvalumab / tremelimumabPhase 1/2 · NCT05932199
- EB-MF-CAR-NK-01Phase 1/2 · NCT07510815
- EnzalutamidePhase 1/2 · NCT04104776
- ErythromycinPhase 1/2 · NCT05579366
- Extended pleurectomy/decortication in case of reaching operabilityPhase 1/2 · NCT07121374
- fludarabinePhase 1/2 · NCT06885697 · NCT03907852 · NCT07510815
- gavo-celPhase 1/2 · NCT03907852
- Gemcitabine and nab-paclitaxelPhase 1/2 · NCT07563738
- HTL0039732 CapsulesPhase 1/2 · NCT05944237
- HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusionPhase 1/2 · NCT05944237
- iCasp9M28z T cell infusionsPhase 1/2 · NCT02414269
- iparomlimab and tuvonralimab (Dual PD-1/CTLA-4 blockade) + chemotherapyPhase 1/2 · NCT07131345
- Ipilimumab and nivolumabPhase 1/2 · NCT07563738
- ISM6331Phase 1/2 · NCT06566079
- ItraconazolePhase 1/2 · NCT05579366
- MDNA11Phase 1/2 · NCT05086692
- MDX2001Phase 1/2 · NCT06239194
- MethoxyaminePhase 1/2 · NCT02535312
- Neoadjuvant chemo-immunotherapyPhase 1/2 · NCT07121374
- Nivolumab & IpilimumabPhase 1/2 · NCT04665206
- ODM-212Phase 1/2 · NCT07563738
- OsimertinibPhase 1/2 · NCT04665206
- Pembrolizumab (KEYTRUDA®)Phase 1/2 · NCT05086692
- Pemetrexed/CarboplatinPhase 1/2 · NCT04665206
- Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumabPhase 1/2 · NCT05932199
- Platinum/pemetrexed based chemotherapyPhase 1/2 · NCT05765084
- Rina-SPhase 1/2 · NCT05579366
- sotorasibPhase 1/2 · NCT07563738
- TNG462Phase 1/2 · NCT05732831
- TT-10Phase 1/2 · NCT04969315
- TT-4Phase 1/2 · NCT04969315
- TulmimetostatPhase 1/2 · NCT04104776
- TYK-01054Phase 1/2 · NCT07282873
- VMD-928 100 mg TabletPhase 1/2 · NCT03556228
- VMD-928 Tablet and Pembrolizumab (200 mg)Phase 1/2 · NCT03556228
- 5-FluorouracilPhase 1 · NCT04847063
- AG-01 CompoundPhase 1 · NCT05627960
- APG-2449Phase 1 · NCT03917043
- AROG4-01Phase 1 · NCT06652529
- Autologous dendritic cellsPhase 1 · NCT03546426
- Avelumab InjectionPhase 1 · NCT04328844
- BGC515Phase 1 · NCT06452160
- CA9hu-1Phase 1 · NCT05698238
- CAR T cellsPhase 1 · NCT04577326
- Cell therapy for solid tumorsPhase 1 · NCT06196294
- Cisplatin or CarboplatinPhase 1 · NCT04162015
- CK-301 (cosibelimab)Phase 1 · NCT03212404
- Combination TherapyPhase 1 · NCT06251310
- DoxorubicinPhase 1 · NCT04847063
- ElimusertibPhase 1 · NCT04491942
- Extrapleural PneumonectomyPhase 1 · NCT03228537
- Gemcitabine HydrochloridePhase 1 · NCT04491942
- HFB200301Phase 1 · NCT05238883
- Hyperthermic Intraperitonial ChemotherapyPhase 1 · NCT04847063
- IAG933Phase 1 · NCT04857372
- IDE397Phase 1 · NCT07277413
- IDE892Phase 1 · NCT07277413
- IMPRINTPhase 1 · NCT04897022
- Indocyanine Green (ICG) Image-Guided SurgeryPhase 1 · NCT03760575
- Interleukin-2Phase 1 · NCT07192900 · NCT03546426
- Interleukin-2 (IL-2)Phase 1 · NCT07443020
- IOA-244Phase 1 · NCT04328844
- KFA115Phase 1 · NCT05544929
- LeucovorinPhase 1 · NCT07532902
- locally manufactured adoptive cellular therapy (ACT) productPhase 1 · NCT07192900 · NCT07443020
- M28z1XXPD1DNR CARPhase 1 · NCT06623396
- MesopherPhase 1 · NCT05304208
- mesothelin expression testingPhase 1 · NCT06885697
- Mitomycin CPhase 1 · NCT04847063
- MRTX1719Phase 1 · NCT05245500
- MT027 cells suspensionPhase 1 · NCT06726564
- Naptumomab estafenatox and durvalumabPhase 1 · NCT03983954
- NX-1607Phase 1 · NCT05107674
- NXP900Phase 1 · NCT05873686
- Obinutuzumab, naptumomab estafenatox and durvalumabPhase 1 · NCT03983954
- OxaliplatinPhase 1 · NCT07532902 · NCT04847063
- PlatinumPhase 1 · NCT07532902
- PleurectomyPhase 1 · NCT03228537
- Radiation TherapyPhase 1 · NCT03228537
- RuxolitinibPhase 1 · NCT04328844
- SHY-ONC6Phase 1 · NCT07705334
- Sodium ThiosulfatePhase 1 · NCT04847063
- SW-682Phase 1 · NCT06251310
- SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CARPhase 1 · NCT05568680
- TLN-499Phase 1 · NCT07713732
- TNhYP218 CAR T CellsPhase 1 · NCT06885697
- VenetoclaxPhase 1 · NCT07713732
- VET3-TGIPhase 1 · NCT06444815
- Implantable Micro- drug delivery Microdevice (IMD)Early phase 1 · NCT07892300
- KT032(anti-MSLN chimeric antigen receptor autologous T cell injection)Early phase 1 · NCT07420010
Closest to patients
- Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)A.O.U. San Luigi Gonzaga · Orbassano, Italy + 18 more hospitalsPhase 3Results expected 2027
- A Phase 3 Trial in Advanced Epithelioid MesotheliomaA Phase 3 Trial in Advanced Epithelioid MesotheliomaVivace Therapeutics, Inc (sponsor)Phase 3Results expected 2028
- PHASE III STUDY WITH ATEZOLIZUMAB VERSUS PLACEBO IN MALIGNANT PLEURAL MESOTHELIOMA PATIENTS AFTER PLEURECTOMY/DECORTICATIONPHASE III STUDY WITH ATEZOLIZUMAB VERSUS PLACEBO IN MALIGNANT PLEURAL MESOTHELIOMA PATIENTS AFTER PLEURECTOMY/DECORTICATIONOspedale Villa Scassi - Sampierdarena-ASL3-Azienda sociosanitaria ligure · Genova-Sampierdarena, Italy + 13 more hospitalsPhase 3
Choose one to continue
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Prognostic factors after multimodality treatment for pleural mesothelioma.
Prognostic factors after multimodality treatment for pleural mesothelioma.
Interdisciplinary cardiovascular and thoracic surgery
PubMed · PMID 42969395Publication
Prognostic associations of PD-L1 expression and BAP1 loss in pleural mesothelioma: a retrospective single-center cohort from Colombia.
Prognostic associations of PD-L1 expression and BAP1 loss in pleural mesothelioma: a retrospective single-center cohort from Colombia.
Frontiers in oncology
PubMed · PMID 42952559
Organisations that can help
Helplines, patient groups and support services for you and your family.
Select your country to see the organisations there, starting with the ones closest to you.
Umbrella organisations (they connect national groups)
European Cancer Patient Coalition (ECPC)
Umbrella of European cancer patient groups, with a patient toolbox and a legal network for cancer patients.
Visit site: European Cancer Patient Coalition (ECPC)European Patients' Forum (EPF)
Umbrella of European patient organisations and national patient coalitions.
Visit site: European Patients' Forum (EPF)
EURORDIS – Rare Diseases Europe
Alliance of over 1,000 rare disease patient organisations, with a list of rare disease helplines by country.
Visit site: EURORDIS – Rare Diseases Europe
International Alliance of Patients' Organizations
Global alliance of patient organisations of all diseases, promoting patient-centred healthcare.
Visit site: International Alliance of Patients' Organizations
Lung Cancer Europe (LuCE)
European umbrella of lung cancer patient groups in 28 countries.
Visit site: Lung Cancer Europe (LuCE)
Frontlight is not affiliated with these organisations; we list them because they help.
Checked automatically every 90 days.
Find fellow researchers
Groups with active Mesothelioma work.
The University of Texas MD Anderson Cancer Center
Houston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
National Cancer Institute
Bethesda, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University of Turin
Turin, Italy
Team details appear once the team leader joins.
Is this your team? Claim it
Mayo Clinic
Rochester, United States
Team details appear once the team leader joins.
Is this your team? Claim it
National Institutes of Health
Bethesda, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
University of Chicago
Chicago, United States
Team details appear once the team leader joins.
Is this your team? Claim it
The Netherlands Cancer Institute
Amsterdam, Netherlands
Team details appear once the team leader joins.
Is this your team? Claim it
University Hospitals of Leicester NHS Trust
Leicester, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Team details appear once the team leader joins.
Is this your team? Claim it
University of Glasgow
Glasgow, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it